Form Approved
OMB No. 0920-xxxx
Exp. Date: XX/XX/20XX
www.cdc.gov/nhsn
Adult Sepsis
Page 1 of 4 |
*required for saving **required for completion |
||||
Facility ID: |
Event #: |
||||
*Patient ID: |
Social Security #: |
||||
Secondary ID: |
Medicare #: |
||||
Patient Name, Last: |
First: |
Middle: |
|||
*Gender: F M Other |
*Date of Birth: |
||||
Ethnicity (Specify): |
|||||
*Event Type: Adult Sepsis |
*Date of Event: |
||||
Post-procedure: Yes No |
Date of Procedure: |
||||
NHSN Procedure Code: |
ICD-10-PCS or CPT Procedure Code: |
||||
*MDRO Infection Surveillance: |
|||||
□ Yes, this infection’s pathogen & location are in-plan for Infection Surveillance in the MDRO/CDI Module |
|||||
□ No, this infection’s pathogen & location are not in-plan for Infection Surveillance in the MDRO/CDI Module |
|||||
*Date Admitted to Facility: |
*Location: |
||||
Event Details |
|||||
Must meet both Part A and B |
|||||
*Part A: Suspected Infection |
|||||
□ Organism identified by culture or non-culture laboratory diagnostic test |
AND |
□ ≥ 4 Qualifying Antimicrobial Days starting within ± 2 calendar days of the collection date for the organism identification culture or non-culture laboratory diagnostic test |
|||
AND |
|||||
*Part B: Organ Dysfunction (Any one of the following within ± 2 calendar days of date when organism identification test was collected – check all that apply) |
|||||
□ Initiation of a new vasopressor |
□ Acute renal failure |
||||
□ Initiation of invasive mechanical ventilation |
□ Hyperbilirubinemia |
||||
□ Serum lactate ≥ 2 mg/dL |
□ Thrombocytopenia |
||||
|
|||||
**If discharged from facility, physical location of patient after leaving facility (Check one): |
|||||
□ Nursing home/skilled nursing facility *if yes, see following question |
|||||
□ Personal residence/Residential care *if yes, see following question |
|||||
□ Other short term general hospital for inpatient care |
|||||
□ Long term acute care hospital |
|||||
□ Hospice inpatient medical facility |
|||||
□ Other facility not specified above |
|||||
□ Unknown |
|||||
|
|||||
**If discharged from the facility to either nursing home/skilled nursing facility or personal residence/residential care, were hospice services arranged for the post-discharge period? |
|||||
□ Yes |
□ No |
||||
**Died: □ Yes □ No |
Sepsis Contributed to Death: □ Yes □ No |
||||
Discharge Date:________________ |
*Pathogens Identified: □ Yes* □ No *If Yes, specify on pages 2-3 |
||||
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 25 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.129 (Front), Rev 0 |
Adult Sepsis
Page 2 of 4 |
||||||||||||
Pathogen # |
Gram-positive Organisms |
|||||||||||
_______ |
Staphylococcus coagulase-negative |
VANC S I R N |
||||||||||
(specify species if available): ____________ |
||||||||||||
_______ |
____Enterococcus faecium
____Enterococcus faecalis
____Enterococcus spp. (Only those not identified to the species level) |
DAPTO S NS N |
GENTHL§ S R N |
LNZ S I R N |
VANC S I R N |
|
||||||
_______ |
Staphylococcus aureus |
CIPRO/LEVO/MOXI S I R N |
CLIND S I R N |
DAPTO S NS N |
DOXY/MINO S I R N |
ERYTH S I R N |
GENT S I R N |
LNZ S R N |
||||
OX/CEFOX/METH S I R N |
RIF S I R N |
TETRA S I R N |
TIG S NS N |
TMZ S I R N |
VANC S I R N |
|
||||||
Pathogen # |
Gram-negative Organisms |
|||||||||||
_______ |
Acinetobacter (specify species) ____________ |
AMK S I R N |
AMPSUL S I R N |
AZT S I R N |
CEFEP S I R N |
CEFTAZ S I R N |
CIPRO/LEVO S I R N |
COL/PB S I R N |
||||
GENT S I R N |
IMI S I R N
|
MERO/DORI S I R N |
PIP/PIPTAZ S I R N |
TETRA/DOXY/MINO S I R N |
||||||||
TMZ S I R N |
TOBRA S I R N |
|
||||||||||
_______ |
Escherichia coli |
AMK S I R N |
AMP S I R N |
AMPSUL/AMXCLV S I R N |
AZT S I R N |
CEFAZ S I R N |
CEFEP S I/S-DD R N |
CEFOT/CEFTRX S I R N |
||||
CEFTAZ S I R N |
CEFUR S I R N |
CEFOX/CETET S I R N |
CIPRO/LEVO/MOXI S I R N |
COL/PB† S R N |
||||||||
ERTA S I R N |
GENT S I R N |
IMI S I R N |
MERO/DORI S I R N |
PIPTAZ S I R N |
TETRA/DOXY/MINO S I R N |
|||||||
TIG S I R N |
TMZ S I R N |
TOBRA S I R N |
|
|||||||||
_______ |
Enterobacter (specify species) ____________ |
AMK S I R N |
AMP S I R N |
AMPSUL/AMXCLV S I R N |
AZT S I R N |
CEFAZ S I R N |
CEFEP S I/S-DD R N |
CEFOT/CEFTRX S I R N |
||||
CEFTAZ S I R N |
CEFUR S I R N |
CEFOX/CETET S I R N |
CIPRO/LEVO/MOXI S I R N |
COL/PB† S R N |
||||||||
ERTA S I R N |
GENT S I R N |
IMI S I R N |
MERO/DORI S I R N |
PIPTAZ S I R N |
TETRA/DOXY/MINO S I R N |
|||||||
TIG S I R N |
TMZ S I R N |
TOBRA S I R N |
|
|||||||||
_______ |
____Klebsiella pneumonia
____Klebsiella oxytoca
|
AMK S I R N |
AMP S I R N |
AMPSUL/AMXCLV S I R N |
AZT S I R N |
CEFAZ S I R N |
CEFEP S I/S-DD R N |
CEFOT/CEFTRX S I R N |
||||
CEFTAZ S I R N |
CEFUR S I R N |
CEFOX/CETET S I R N |
CIPRO/LEVO/MOXI S I R N |
COL/PB† S R N |
||||||||
ERTA S I R N |
GENT S I R N |
IMI S I R N |
MERO/DORI S I R N |
PIPTAZ S I R N |
TETRA/DOXY/MINO S I R N |
|||||||
TIG S I R N |
TMZ S I R N |
TOBRA S I R N |
|
Adult Sepsis
Page 3 of 4 |
||||||||||||||||||
Pathogen # |
Gram-negative Organisms (continued) |
|||||||||||||||||
_______ |
Pseudomonas aeruginosa |
AMK S I R N |
AZT S I R N |
CEFEP S I R N |
CEFTAZ S I R N |
CIPRO/LEVO S I R N |
COL/PB S I R N |
GENT S I R N |
||||||||||
|
|
IMI S I R N
|
MERO/DORI S I R N |
PIP/PIPTAZ S I R N |
TOBRA S I R N |
|||||||||||||
Pathogen # |
Fungal Organisms |
|||||||||||||||||
_______ |
Candida (specify species if available) ____________
|
ANID S I R N |
CASPO S NS N |
FLUCO S S-DD R N |
FLUCY S I R N |
ITRA S S-DD R N |
MICA S NS N |
VORI S S-DD R N |
||||||||||
Pathogen # |
Other Organisms |
|||||||||||||||||
_______ |
Organism 1 (specify) ____________
|
_______Drug 1 S I R N |
_______ Drug 2 S I R N |
______ Drug 3 S I R N |
_______ Drug 4 S I R N |
_______Drug 5 S I R N |
______ Drug 6 S I R N |
______ Drug 7 S I R N |
______ Drug 8 S I R N |
______ Drug 9 S I R N |
||||||||
_______ |
Organism 1 (specify) ____________
|
_______Drug 1 S I R N |
_______ Drug 2 S I R N |
______ Drug 3 S I R N |
_______ Drug 4 S I R N |
_______Drug 5 S I R N |
______ Drug 6 S I R N |
______ Drug 7 S I R N |
______ Drug 8 S I R N |
______ Drug 9 S I R N |
||||||||
_______ |
Organism 1 (specify) ____________
|
_______Drug 1 S I R N |
_______ Drug 2 S I R N |
______ Drug 3 S I R N |
_______ Drug 4 S I R N |
_______Drug 5 S I R N |
______ Drug 6 S I R N |
______ Drug 7 S I R N |
______ Drug 8 S I R N |
______ Drug 9 S I R N |
Result Codes
S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested
§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic
† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4
Drug Codes: |
|
|
|
AMK = amikacin |
CEFTRX = ceftriaxone |
FLUCY = flucytosine |
OX = oxacillin |
AMP = ampicillin |
CEFUR= cefuroxime |
GENT = gentamicin |
PB = polymyxin B |
AMPSUL = ampicillin/sulbactam |
CETET= cefotetan |
GENTHL = gentamicin –high level test |
PIP = piperacillin |
AMXCLV = amoxicillin/clavulanic acid |
CIPRO = ciprofloxacin |
IMI = imipenem |
PIPTAZ = piperacillin/tazobactam |
ANID = anidulafungin |
CLIND = clindamycin |
ITRA = itraconazole |
RIF = rifampin |
AZT = aztreonam |
COL = colistin |
LEVO = levofloxacin |
TETRA = tetracycline |
CASPO = caspofungin |
DAPTO = daptomycin |
LNZ = linezolid |
TIG = tigecycline |
CEFAZ= cefazolin |
DORI = doripenem |
MERO = meropenem |
TMZ = trimethoprim/sulfamethoxazole |
CEFEP = cefepime |
DOXY = doxycycline |
METH = methicillin |
TOBRA = tobramycin |
CEFOT = cefotaxime |
ERTA = ertapenem |
MICA = micafungin |
VANC = vancomycin |
CEFOX= cefoxitin |
ERYTH = erythromycin |
MINO = minocycline |
VORI = voriconazole |
CEFTAZ = ceftazidime |
FLUCO = fluconazole |
MOXI = moxifloxacin |
|
Adult Sepsis
Page 4 of 4 |
|||
Custom Fields |
|||
Label |
Label |
||
______________________ |
____/____/____ |
_______________________ |
____/____/_____ |
_______________________ |
_____________ |
_______________________ |
______________ |
_______________________ |
_____________ |
_______________________ |
______________ |
_________________________ |
______________ |
_______________________ |
______________ |
_________________________ |
______________ |
_______________________ |
______________ |
_________________________ |
______________ |
_______________________ |
______________ |
_________________________ |
______________ |
_______________________ |
______________
|
Comments |
|||
|
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
File Title | 57.112_VAE |
Author | Amy Schneider;CDC |
File Modified | 0000-00-00 |
File Created | 2023-11-20 |